LY-207702

N/A

Report date: 2024/11/29 16:57:22
NME

Base Information

Drug NameLY-207702
Drug Alias NamedFdAP
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Nucleosides and nucleotide derivtives
Mechanisms of ActionRibonucleotide reductase inhibitors
TargetsRibonucleotide reductase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A